Ultra large volume wearable injectors are devices specially designed to stick to the body. These devices work on different mechanisms to deliver drug to the patient through subcutaneous route over an extended period of time. Furthermore, these devices have drug reservoirs that can store drugs solution of 2ml or more then 2ml. For instance, these devices function on mechanisms such as electromechanical, mechanical, and others. In addition, the electromechanical devices work with the help of electrical motor, which is responsible to build pressure for drug delivery. However, mechanical devices use osmosis to deliver the drug to the body of the patient. Furthermore, there are different benefits associated with the use of these devices. These include better patient compliance as this eliminates the need of frequent drug administration, easy ambulation as the patient is not tethered to an IV line, self-administration which lowers the frequency of healthcare professional visits, and others. In addition, these devices are used for the treatment of various chronic conditions such as cancer, diabetes, Parkinson’s diseases, and others.
The major factor that contributes toward the growth of the ultra large volume wearable injectors market include surge in prevalence of chronic disorders such as diabetes, cancer, and others. Furthermore, other factors such as benefits associated with the use of ultra large volume wearable injectors and rise in adoption of these devices across the globe fuel the growth of the market.
Moreover, surge in the demand of more advanced treatment options for chronic diseases such as diabetes contributes toward the growth of the market. In addition, increase in focus by key players toward launch of new products in the market has led to rise in collaborations within the market, which fuels the growth of the market. However, high price of ultra large volume wearable devices restrict the global ultra large volume wearable injectors market growth. In contradiction, presence of ultra large volume wearable devices in development phase, which are expected to be introduced during the forecast period is expected to provide lucrative opportunities for the players in the market.
The ultra large volume wearable injectors market is segmented on the basis of product type, application, and region to provide a detailed assessment of the market. By product type, the market is divided into electromechanical wearable injectors and others. By application, it is classified into diabetes, cancer and others. By region, the ultra large volume wearable injector market size is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Major players operating in the market include Amgen Inc., Becton, Dickinson And Company, CeQur SA, Enable Injections, Inc., Gerresheimer AG (Sensile Medical AG), Insulet Corporation, Medtronic plc., Tandem Diabetes Care, Inc., West Pharmaceutical Services, Inc., and Ypsomed Holding AG.
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis along with the current global antihypertensive market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
KEY MARKET SEGMENTS
By Product Type
- Electromechanical Wearable Injectors
- Others
By Application
- Diabetes
- Cancer
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
List of key players profiled in the report
- Amgen Inc.
- Becton, Dickinson And Company
- CeQur SA
- Enable Injections, Inc.
- Gerresheimer AG (Sensile Medical AG)
- Insulet Corporation
- Medtronic plc.
- Tandem Diabetes Care, Inc.
- West Pharmaceutical Services, Inc.,
- Ypsomed Holding AG
LIST OF OTHER PLAYERS IN THE VALUE CHAIN(These players are not profiled in the report. The same will be included on request.)
- E3D Elcam Drug Delivery Devices.
- Subcuject ApS
Table of Contents
Executive Summary
According to the report titled 'Ultra-Large Volume Wearable Injectors Market by Product Type and Application: Global Opportunity Analysis and Industry Forecast, 2019-2026,' the global ultra-large volume wearable injectors market was valued at $1 billion in 2018, and is expected to reach $4 billion by 2026, registering a CAGR of 14.2% from 2019 to 2026.Ultra large volume wearable injector is defined as the device capable of delivery of large volume of drug to the body of a patient over an extended period of time. Furthermore, these devices can deliver a drug solution of volume 2ml or more through the subcutaneous route. These are defined as wearable injectors as the devices have self-adhesive back, which can be applied to the body of the patient.
In addition, the drug delivery depends on the mechanism of the device such as electromechanical wearable injectors deliver drug with the help of electric motor that builds pressure required for drug delivery. The other type of mechanism includes the drugs delivery, which is based on osmosis mechanism. Moreover, these devices are used in the treatment of diseases such as diabetes, cancer, and others.
Surge in the prevalence of chronic disorders such as diabetes, cancer, and others is the major factor that contributes toward the growth of the ultra large volume wearable injectors market. In addition, surge in the demand for more advanced treatment options for chronic diseases such as diabetes boosts the growth of the market. In addition, increase in focus by key players toward launch of new products in the market has led to rise in collaborations with in the market which also fuels the growth of the market. Moreover, other factors such as benefits associated with the use of ultra large volume wearable injectors and rise in the adoption of these devices across the globe fuel the market growth. However, high price of ultra large volume wearable devices restrict the growth of the global ultra large volume wearable injectors market during the forecast period.
In contradiction, presence of ultra large volume wearable devices in development phase, which are expected to be introduced during the forecast period is expected to provide lucrative opportunities for the players in the market.
The ultra large volume wearable injectors market is segmented on the basis of product type, application, and region to provide a detailed assessment of the market. By product type, the market is divided into electromechanical wearable injectors and others. By application, it is classified into diabetes, cancer, and others. By region, the ultra large volume wearable injector market size is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, rest of Asia-Pacific and others), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
On the basis of product type, the market is divided into electromechanical wearable injector, and others. Electromechanical wearable injector acquired the major share of the ultra large volume wearable injectors market and is expected to exhibit the fastest growth rate during the forecast period. The growth of this segment is attributable to surge in prevalence cancer and diabetes worldwide. Moreover, rise in awareness related to use of ultra large volume wearable injectors and surge in demand for advanced treatment options for chronic diseases such as diabetes fuel the growth of the market. Furthermore, presence of large number of electromechanical wearable injectors is another major factor that contributes to the growth of the market.
By application, the market is segmented into diabetes, cancer and others, research laboratories, and others. The diabetes segment occupied the largest share of the market in 2018 and is expected to maintain the lead during the forecast period.
The growth of this segment is attributable to the presence of large number of ultra large volume wearable injectors, which are used to treat diabetes. Furthermore, the cancer segment is expected to exhibit fastest growth rate during the forecast period owing to surge in wide spread prevalence of cancer across the globe.
According to Onkar Sumant, Manager, Healthcare, “The demand for ultra-large volume wearable injectors is on a rise, owing to surge in incidence of chronic diseases such as diabetes and cancer. Furthermore, rise in awareness related to use of ultra-large volume wearable injectors across the globe is another factor that fuels the growth of the market.”
KEY FINDINGS OF THE STUDY
- By type, the electromechanical wearable injectors segment occupied more than three-fourth share of the global ultra large volume wearable injectors market in 2018.
- By application, the cancer segment is anticipated to grow with the highest CAGR throughout the forecast period
- By application, the diabetes segment accounted for two-third share of the market in 2018.
- By region, Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.
Companies Mentioned
- Amgen Inc.
- Becton
- Dickinson And Company
- CeQur SA
- Enable Injections Inc.
- Gerresheimer AG (Sensile Medical AG)
- Insulet Corporation
- Medtronic plc.
- Tandem Diabetes Care Inc.
- West Pharmaceutical Services Inc.
- Ypsomed Holding AG.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...